Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Escolar

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|April 27, 2007
CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophyGunnar M Buyse, Nathalie Goemans, Erik Henricson, et al.
Human Genetics|June 18, 2003
Genome-wide homozygosity mapping localizes a gene for autosomal recessive non-progressive infantile ataxia to 20q11-q13Lisbeth Tranebjaerg, Tanya M Teslovich, MaryPat Jones, et al.
Muscle & Nerve|June 16, 2011
Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophyAngela Zimmerman, Paula R Clemens, Carolina Tesi-Rocha, et al.
Muscle & Nerve|May 17, 2013
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods usedCraig M McDonald, Erik K Henricson, R Ted Abresch, et al.
Muscle & Nerve|June 24, 2011
CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophyChristopher F Spurney, Carolina Tesi Rocha, Erik Henricson, et al.
Muscle & Nerve|September 26, 2008
Clinical features of late-onset Pompe disease: a prospective cohort studyJohn H J Wokke, Diana M Escolar, Alan Pestronk, et al.
Muscle & Nerve|May 8, 2013
The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measuresErik K Henricson, R Ted Abresch, Avital Cnaan, et al.
Journal of Psychiatric Research|July 31, 2021
Social Cognition and Interaction Training (SCIT) versus Training in Affect Recognition (TAR) in patients with schizophrenia: A randomized controlled trialG Lahera, A Reboreda, A Vallespí, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2020
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>Eleni Anastasiadou, Anita G Seto, Xuan Beatty, et al.
Neurology|June 11, 2003
PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndromeM R Donaldson, J L Jensen, M Tristani-Firouzi, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|April 27, 2007
CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophyGunnar M Buyse, Nathalie Goemans, Erik Henricson, et al.
Human Genetics|June 18, 2003
Genome-wide homozygosity mapping localizes a gene for autosomal recessive non-progressive infantile ataxia to 20q11-q13Lisbeth Tranebjaerg, Tanya M Teslovich, MaryPat Jones, et al.
Muscle & Nerve|June 16, 2011
Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophyAngela Zimmerman, Paula R Clemens, Carolina Tesi-Rocha, et al.
Muscle & Nerve|May 17, 2013
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods usedCraig M McDonald, Erik K Henricson, R Ted Abresch, et al.
Muscle & Nerve|June 24, 2011
CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophyChristopher F Spurney, Carolina Tesi Rocha, Erik Henricson, et al.
Muscle & Nerve|September 26, 2008
Clinical features of late-onset Pompe disease: a prospective cohort studyJohn H J Wokke, Diana M Escolar, Alan Pestronk, et al.
Muscle & Nerve|May 8, 2013
The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measuresErik K Henricson, R Ted Abresch, Avital Cnaan, et al.
Journal of Psychiatric Research|July 31, 2021
Social Cognition and Interaction Training (SCIT) versus Training in Affect Recognition (TAR) in patients with schizophrenia: A randomized controlled trialG Lahera, A Reboreda, A Vallespí, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2020
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>Eleni Anastasiadou, Anita G Seto, Xuan Beatty, et al.
Neurology|June 11, 2003
PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndromeM R Donaldson, J L Jensen, M Tristani-Firouzi, et al.
Pageof 5